Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm
Gothenburg,September 16, 2019- On September 11, 2019, Vicore Pharma Holding AB (publ) (”Vicore” or the “Company”) announced that Nasdaq Stockholm’s listing committee had approved that the Company’s shares are admitted to trading on Nasdaq Stockholm’s main market. Today, on September 16, 2019, the prospectus that has been prepared in connection with the listing was approved and registered by the Swedish Financial Supervisory Authority and is now available on Vicore’s website, www.vicorepharma.com.
The first day of trading on Nasdaq Stockholm’s main market is September 27, 2019. The last day of trading on Nasdaq First North Growth Market is September 26, 2019.
For further information, please contact:
Carl-Johan Dalsgaard, CEO tel: +46 (0)70 975 98 63, carl-johan.dalsgaard@vicorepharma.com
Hans Jeppsson, CFO, tel: +46 (0)70-553 14 65, hans.jeppsson@vicorepharma.com
The information was submitted for publication through the agency of the contact persons set out above, at 17.30 CEST on September 16, 2019.
Source: Vicore Pharma
